Clinical Trials Logo

Clinical Trial Summary

There is no specific therapy for acute kidney injury. It is presumed that supportive measures improve the care and outcome of patients with acute kidney injury. To investigate whether an implementation of a supportive extended care "bundle" in high-risk patients for persistent acute kidney injury (AKI) can reduce the occurrence of persistent surgical AKI. In order to investigate whether the extended KDIGO bundle can prevent persistent AKI in patients with high chemokine ligand 14 (CCL14) as well as in patients with low CCL14, patients will be randomized with stratification by the CCL-value.


Clinical Trial Description

All patients will receive standard of care therapy according to the standards of our center. After identifying surgical patients with a moderate or severe (stage 2 or 3) AKI patients will be randomly allocated to the control or intervention group according to the CCL14 results which will be measured as part of the study. According to the literature, patients with a CCL14 <1.3ng/ml are at low risk of progression and patients with a CCL14≥1.3ng/ml are at high risk of AKI progression. In order to have both patient groups included, we will have two groups (patients at low and at high risk of AKI progression) and these will be randomized to receive either standard of care or an extended KDIGO bundle (in total 4 groups). Control intervention / reference test: Patients in the control groups will be treated according to the standard of care. The only two hemodynamic targets in this group are the mean arterial pressure (mean arterial pressure (MAP)>65mmHg) and passive leg raising test (PLRT) (increase of cardiac output (CO) <10%). In the intervention groups, an extended KDIGO guideline bundle will be implemented (Discontinuation of all nephrotoxic agents when possible, optimization of volume status and perfusion pressure, consideration of a functional hemodynamic monitoring, close monitoring of serum creatinine and urine output, avoidance of hyperglycemia, consideration of alternatives to radio contrast agents, non-invasive or invasive diagnostic workup, nephrology consultation) ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05275218
Study type Interventional
Source University Hospital Muenster
Contact Zarbock, MD
Phone +49-251-8347252
Email aki@anit.uni-muenster.de
Status Recruiting
Phase N/A
Start date March 22, 2023
Completion date May 2025

See also
  Status Clinical Trial Phase
Completed NCT02248051 - Open-Label Safety, Tolerability, PK Study of IV CXA-10 Emulsion in Subjects in Chronic Kidney Injury Phase 1
Completed NCT03244514 - Biomarker-guided Implementation of the AKI Bundle N/A
Withdrawn NCT04598516 - Maastricht Investigation of Renal Function in Absence of- and Post- Contrast in Patients With eGFR LEss Than 30
Recruiting NCT06259760 - AKI Risk Factors Analysis After Intentional Hypotensive Anesthesia
Recruiting NCT06295393 - Renin Angiotensin Aldosterone System In Septic Kids
Completed NCT03453996 - Contrast RISK (Reducing Injury Sustained by Kidneys) N/A
Recruiting NCT02095275 - Exploring the Relationship Among BNP, Fluid Status and Acute Kidney Injury in Critically Ill Patients N/A
Not yet recruiting NCT03369561 - Comparison Between Right and Left Ventricular Systolic Dysfunction as a Risk Factors for Aki in Critical Care Patients N/A
Completed NCT05612802 - A New Marker for Early Diagnosis of Pneumoperitoneum-Related Acute Kidney Injury: Insulin-Like Growth Factor-1 (IGF-1) N/A
Not yet recruiting NCT03830450 - Biomarkers of Acute Kidney Injury in Cardiac Surgery
Completed NCT04592406 - Data on the Prevention of Complications of Prophylactic Intravenous Hydration in Patients With eGFR < 30
Completed NCT02127190 - Study of CXA-10 in Healthy Volunteers Phase 1